ArticleNature communications2021
Integrin-α
Open access · goldAbstract read
In one paragraph
Article in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.
0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
4.8field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 66 citations in OpenAlex.
- Select intratumoral riboflavin-auxotrophicProceedings of the National Academy of Sciences of the United States of America · 2026Article
- Integrin-mediated mechanotransduction in the tumor microenvironment: macrophage-centered signaling mechanisms and immune remodeling.Journal of translational medicine · 2026Review
- Temporal Dissection of TGF-β signaling reveals differential impact during female reproductive mucosal CD8 resident memory T cell differentiation.Mucosal immunology · 2026Article
- Bottom-Up Programming of Cell States in Cancer Organoids with Defined Synthetic Adhesion Cues.Advanced materials (Deerfield Beach, Fla.) · 2026Article
- Transcriptional Profile Change of NK-92 Cells in Presence of Cytokines, TGFβ Signaling Pathway Inhibitor and CDK7/12/13 Kinase Inhibitor.International journal of molecular sciences · 2026Article
- Proteogenomic decoding of chemotherapy resistance in patients with triple-negative breast cancer.Genome biology · 2026Article
- [Protein Expression Levels of the DCAF4-MEN1-hTERT Axis in Patients With Colon Adenocarcinoma and Their Relationship With Clinicopathological Characteristics and Prognosis].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026Article
- CAF-derived exosomal circMPP6 drives ovarian cancer metastasis by coordinating nuclear and cytoplasmic regulation of ADAM22 to activate TGF-β/Smad signaling.International journal of biological sciences · 2026Article
- Nanosystem-Mediated Intercellular Crosstalk Modulation in the Tumor Microenvironment for Enhanced Cancer Immunotherapy.Drug design, development and therapy · 2026Review
- Fibroblast activation protein (FAP)-mediated promotion of metastasis via the FN1-TGFβ axis and immune suppression in aggressive thyroid cancer.Journal of translational medicine · 2025Article
- Unlocking the therapeutic potential of cellular mechanobiology.Science advances · 2025Review
- A Novel Bispecific Integrin α5β1/αv Antibody Reprograms the Myc-Regulated Basal Phenotype of Prostate Cancer with NK Cell-Mediated Tumor Elimination.Molecular cancer research : MCR · 2025Article
- Dopant-Regulated Piezocatalysts Evoke Sonopiezoelectric and Enzymatic PANoptosis for Synergistic Cancer Therapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- The immunoregulatory role of integrins in pulmonary diseases.Frontiers in immunology · 2025Review
- Keeping it local: how CD8 TRMs regulate viral and cancer immunity.Frontiers in immunology · 2025Review
- ADAM Metallopeptidase domain 19 promotes skin fibrosis in systemic sclerosis via neuregulin-1.Molecular medicine (Cambridge, Mass.) · 2024Article
- The integrin adhesome and control of anti-tumour immunity.Biochemical Society transactions · 2024Review
- Tissue-resident memory cells in antitumoral immunity and cancer immunotherapy.Current opinion in immunology · 2024Review
- IGF1R signaling induces epithelial-mesenchymal plasticity via ITGAV in cutaneous carcinoma.Journal of experimental & clinical cancer research : CR · 2024Article
- Humanin activates integrin αV-TGFβ axis and leads to glioblastoma progression.Cell death & disease · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 5 institutions in 3 countries.
Ines MalenicaINSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-Univ. Paris-Sud, Université Paris-Saclay, Villejuif, France.
Julien Adam *INSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-Univ. Paris-Sud, Université Paris-Saclay, Villejuif, France.
Stéphanie Corgnac *INSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-Univ. Paris-Sud, Université Paris-Saclay, Villejuif, France.ORCID 0000-0002-3014-9178
Laura MezquitaDepartment of Cancer Medicine, Gustave Roussy Cancer Campus, Institut d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Edouard AuclinMedical and Thoracic Oncology Department, Hôpital Européen Georges Pompidou, AP-HP, Paris, France.
Isabelle DameiINSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-Univ. Paris-Sud, Université Paris-Saclay, Villejuif, France.
Laetitia GrynszpanINSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-Univ. Paris-Sud, Université Paris-Saclay, Villejuif, France.
Gwendoline GrosINSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-Univ. Paris-Sud, Université Paris-Saclay, Villejuif, France.
Vincent de MontprévilleINSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-Univ. Paris-Sud, Université Paris-Saclay, Villejuif, France.ORCID 0000-0001-7490-4000
David PlanchardDepartment of Cancer Medicine, Gustave Roussy Cancer Campus, Institut d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Nathalie ThéretUniv Rennes, Inserm, EHESP, Irset-UMR-S1085, Rennes, France.ORCID 0000-0002-5857-7828
Benjamin BesseDepartment of Cancer Medicine, Gustave Roussy Cancer Campus, Institut d'Oncologie Thoracique, Gustave Roussy, Université Paris-Saclay, Villejuif, France.
Fathia Mami-ChouaibINSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Fac. de Médecine-Univ. Paris-Sud, Université Paris-Saclay, Villejuif, France. fathia.mami-chouaib@gustaveroussy.fr.ORCID 0000-0001-9685-6011
Université Paris-Sud · FRUniversité Paris-Saclay · FRAssistance Publique – Hôpitaux de Paris · FRBreast Cancer Research Foundation · USInserm · FR
Funding
No grant is acknowledged in the PubMed record.
Abstract
TGF-β is secreted in the tumour microenvironment in a latent, inactive form bound to latency associated protein and activated by the integrin α
Indexed as
AnimalsAntigens, CDB7-H1 AntigenCD8-Positive T-LymphocytesCell Line, TumorFemaleHumansImmunotherapyIntegrin alpha ChainsIntegrin alphaVLung NeoplasmsLymphocytes, Tumor-InfiltratingMiceMice, Inbred C57BLProgrammed Cell Death 1 ReceptorTransforming Growth Factor betaalpha E integrinsAntigens, CDB7-H1 AntigenCD274 protein, humanIntegrin alpha ChainsIntegrin alphaVProgrammed Cell Death 1 ReceptorTransforming Growth Factor beta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.